The Medical Letter on Drugs and Therapeutics
ONLINE
ONLY
ARTICLE
November 14, 2022
View Complete Issue         Table of Contents 2019 
Alpelisib (Vijoice) for PIK3CA-Related Overgrowth Spectrum (online only)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Alpelisib (Vijoice) for PIK3CA-Related Overgrowth Spectrum (online only)
November 14, 2022 (Issue: 1663)
The oral kinase inhibitor alpelisib (Vijoice – Novartis) has been approved by the FDA for treatment of patients ≥2 years old with severe manifestations of PIK3CA-related overgrowth spectrum (PROS) who require systemic treatment. Alpelisib is...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Alpelisib (Vijoice) for PIK3CA-Related Overgrowth Spectrum (online only)
Article code: 1663c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.